Company intelligence / Profile preview

Calcilytix Therapeutics

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Calcilytix Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare disorders of calcium and phosphate metabolism. The company's lead program, encaleret, is an investigational small molecule calcilytic designed to antagonize the calcium-sensing receptor (CaSR). By inhibiting CaSR, encaleret aims to restore normal parathyroid hormone secretion and normalize blood calcium levels in patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1). Originally established as a subsidiary of BridgeBio Pharma, Calcilytix was acquired by Alexion, AstraZeneca Rare Disease, in 2022 to expand their late-stage rare disease endocrinology portfolio.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

encaleret

Beyond the preview

Go deeper on Calcilytix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcilytix Therapeutics.

Explore the full profile